Carcinogenesis, prevention and early detection of gastric cancer: Where we are and where we should go
Corresponding Author
Carlos A. González
Unit of Nutrition, Environment and Cancer, Epidemiology Research Programme, Catalan Institut of Oncology, Hospitalet del Llobregat, Barcelona
Unit of Nutrition, Environment and Cancer, Catalan Institute of Oncology – IDIBELL. Gran Via de l'Hospitalet 199-203, 08907- Hospitalet de Llobregat, Barcelona (Spain)Search for more papers by this authorAntonio Agudo
Unit of Nutrition, Environment and Cancer, Epidemiology Research Programme, Catalan Institut of Oncology, Hospitalet del Llobregat, Barcelona
Search for more papers by this authorCorresponding Author
Carlos A. González
Unit of Nutrition, Environment and Cancer, Epidemiology Research Programme, Catalan Institut of Oncology, Hospitalet del Llobregat, Barcelona
Unit of Nutrition, Environment and Cancer, Catalan Institute of Oncology – IDIBELL. Gran Via de l'Hospitalet 199-203, 08907- Hospitalet de Llobregat, Barcelona (Spain)Search for more papers by this authorAntonio Agudo
Unit of Nutrition, Environment and Cancer, Epidemiology Research Programme, Catalan Institut of Oncology, Hospitalet del Llobregat, Barcelona
Search for more papers by this authorAbstract
Helicobacter pylori is the most common cause of gastric cancer (GC), though smoking, alcohol, diet, genetics and epigenetic factors may also have a role in the occurrence of the disease. Why H. pylori cause GC in only a minority of those infected remains unknown. Although mechanisms of H. pylori-induced carcinogenesis are not yet well understood, several genotypes of H. pylori have been associated with strain virulence and disease risk. Primary prevention of GC should be addressed by avoiding exposure to factors that increase the risk and to promote factors associated with decrease risk. Vaccines against H. pylori are an ongoing promise and not yet available. Chemoprevention through vitamin supplementation has shown no benefit. Screening and eradication of H. pylori in the general population is not advised. Given that GC is a multiple-steps process, the identification of patients with preneoplastic lesions with high risk of progression, and periodic endoscopic surveillance of them represents the most effective way for early diagnosis of GC. However, clinical guidelines for surveillance are lacking and there are no clear criteria to classify patients into high or low risk of progressing to GC. No study has shown the potential usefulness of combining the information on the type of preneoplastic lesions, genetic and epigenetic, lifestyle and virulence bacterial factors in order to identify high risk patients who need more intensive surveillance. The integration of all this information, in a prediction model requires further research and could be the most important contribution for reducing the burden of GC.
References
- 1 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–917.
- 2 Herrera V, Parsonnet J. Helicobacter pylori and gastric adenocarcinoma. Clin Microbiol Infect 2009; 15: 971–6.
- 3 Chandanos E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer 2008; 44: 2397–403.
- 4 IARC Monographs on the evaluation of carcinogenic risks to humans. Volume 61. IARC Monographs. Lyon 1994.
- 5 Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49: 347–53.
- 6 Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030–44.
- 7 Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 2004; 159: 252–8.
- 8 IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 83. Lyon, 2004. Tobacco Smoke and Involuntary Smoking.
- 9 González CA, Pera G, Agudo A, Palli D, Krogh V, Vineis P, Tumino R, Panico S, Berglund G, Simán H, Nyrén O, Agren A, et al. Smoking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). Int J Cancer 2003; 107: 629–34.
- 10 Food, nutrition, physical activity, and the prevention of cancer: a global perspective. WCRF/AICR. Washington 2007.
- 11 Bae JM, Lee EJ, Guyatt G. Citrus fruit intake and stomach cancer risk: a quantitative systematic review. Gastric Cancer 2008; 11: 23–32. Epub 2008 Mar 29. Review. Erratum in: Gastric Cancer 2008;11:127.
- 12 González CA, Jakszyn P, Pera G, Agudo A, Bingham S, Palli D, Ferrari P, Boeing H, del Giudice G, Plebani M, Carneiro F, Nesi G, et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006; 98: 345–54.
- 13 Larsson SC, Orsini N, Wolk A. Processed meat consumption and stomach cancer risk: a meta-analysis. J Natl Cancer Inst 2006; 98: 1078–87.
- 14 Jakszyn P, Bingham S, Pera G, Agudo A, Luben R, Welch A, Boeing H, Del Giudice G, Palli D, Saieva C Krogh V, Sacerdote C, et al. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis 2006; 27: 1497–501.
- 15 Vainio H, Kaaks R, Bianchini F. Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev 2002; 11: S94–S100.
- 16 Tramacere I, Negri E, Pelucchi C, Bagnardi V, Rota M, Scotti L, Islami F, Corrao G, La Vecchia C, Boffetta P. A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol 2011 May 2. Epub ahead of print.
- 17 Lindblad M, Ye W, Rubio C, Lagergren J. Estrogen and risk of gastric cancer: a protective effect in a nationwide cohort study of patients with prostate cancer in Sweden. Cancer Epidemiol Biomarkers Prev 2004; 13: 2203–7.
- 18 Yaghoobi M, Bijarchi R, Narod SA. Family history and the risk of gastric cancer. Br J Cancer 2010; 102: 237–42.
- 19 Carneiro F, Oliveira C, Suriano G, Seruca R. Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer. J Clin Pathol 2008; 61: 25–30.
- 20 González CA, Sala N, Capellá G. Genetic susceptibility and gastric cancer risk. Int J Cancer 2002; 100: 249–60.
- 21 Shanks AM, El-Omar EM. Helicobacter pylori infection, host genetics and gastric cancer. J Dig Dis 2009; 10: 157–64.
- 22 Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, Vaughan TL, McColl KE, Lissowska J, Zatonski W, Schoenberg JB, Blot WJ, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007; 132: 905–12.
- 23 Wang P, Xia HH, Zhang JY, Dai LP, Xu XQ, Wang KJ. Association of interleukin-1 gene polymorphisms with gastric cancer: a meta-analysis. Int J Cancer 2007; 120: 552–62.
- 24 Persson C, Canedo P, Machado JC, El-Omar EM, Forman D. Polymorphisms in inflammatory response genes and their association with gastric cancer: a HuGE systematic review and meta-analyses. Am J Epidemiol 2011; 173: 259–70.
- 25 Wang J, Pan HF, Hu YT, Zhu Y, He Q. Polymorphism of IL-8 in 251 allele and gastric cancer susceptibility: a meta-analysis. Dig Dis Sci 2010; 55: 1818–23.
- 26 Zhuang W, Wu XT, Zhou Y, Liu L, Liu GJ, Wu TX, Yao X, Du L, Wei ML. Interleukin10 -592 promoter polymorphism associated with gastric cancer among Asians: a meta-analysis of epidemiologic studies. Dig Dis Sci 2010; 55: 1525–32.
- 27 Lu PH, Tang Y, Li C, Shen W, Ji L, Guo YJ, Tao GQ. Meta-analysis of association of tumor necrosis factor alpha-308 gene promoter polymorphism with gastric cancer. Zhonghua Yu Fang Yi Xue Za Zhi 2010; 44: 209–14.
- 28 Dong J, Dai J, Zhang M, Hu Z, Shen H. Potentially functional COX-2–1195G>A polymorphism increases the risk of digestive system cancers: a meta-analysis. J Gastroenterol Hepatol 2010; 25: 1042–50.
- 29 Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004; 4: 45–60.
- 30 Saeki N, Saito A, Choi IJ, Matsuo K, Ohnami S, Totsuka H, Chiku S, Kuchiba A, Lee YS, Yoon KA, Kook MC, Park SR, et al. A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer. Gastroenterology 2011; 140: 892–902.
- 31 Boccia S, De Lauretis A, Gianfagna F, van Duijn CM, Ricciardi G. CYP2E1PstI/RsaI polymorphism and interaction with tobacco, alcohol and GSTs in gastric cancer susceptibility: a meta-analysis of the literature. Carcinogenesis 2007; 28: 101–6.
- 32 Chen B, Cao L, Zhou Y, Yang P, Wan HW, Jia GQ, Liu L, Wu XT. Glutathione S-transferase T1 (GSTT1) gene polymorphism and gastric cancer susceptibility: a meta-analysis of epidemiologic studies. Dig Dis Sci 2010; 55: 1831–8.
- 33 Chen B, Zhou Y, Yang P, Wu XT. Glutathione S-transferase M1 gene polymorphism and gastric cancer risk: an updated analysis. Arch Med Res 2010; 41: 558–66.
- 34 Zhou Y, Li N, Zhuang W, Yin YQ, Liu GJ, Wu TX, Yao X, Du L, Wei ML, Wu XT. Glutathione S-transferase P1 gene polymorphism associated with gastric cancer among Caucasians. Eur J Cancer 2009; 45: 1438–42.
- 35 Zhong X, Hui C, Xiao-Ling W, Yan L, Na L. NAT2 polymorphism and gastric cancer susceptibility: a meta-analysis. Arch Med Res 2010; 41: 275–80.
- 36 Xue H, Ni P, Lin B, Xu H, Huang G. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and gastric cancer risk: A HuGE review and meta-analysis. Am J Epidemiol 2011; 173: 363–75.
- 37 Chen B, Zhou Y, Yang P, Wu XT. ERCC2 Lys751Gln and Asp312Asn polymorphisms and gastric cancer risk: a meta-analysis. J Cancer Res Clin Oncol 2011; 137: 939–46.
- 38 Fang F, Wang J, Yao L, Yu XJ, Yu L, Yu L. Relationship between XRCC3 T241M polymorphism and gastric cancer risk: a meta-analysis. Med Oncol 2010 Jun 12. DOI: 10.1007/s12032-010-9591-3.
- 39 Dong X, Wu J, Liang P, Li J, Yuan L, Liu X. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer: a meta-analysis. Arch Med Res 2010; 41: 125–33.
- 40 Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, Du L, Wei ML, Wu XT. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 2007; 121: 1481–6.
- 41 Study Group of Millennium Genome Project for Cancer, Sakamoto H, Yoshimura K, Saeki N,Katai H Shimoda T, Matsuno Y, Saito D, Sugimura H, Tanioka F, Kato S, Matsukura N, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 2008; 40: 730–40.
- 42 Abnet CC, Freedman ND, Hu N, Wang Z, Yu K, Shu XO, Yuan JM, Zheng W, Dawsey SM, Dong LM, Lee MP, Ding T, et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet 2010; 42: 764–7.
- 43 Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148–59.
- 44 Sato F, Meltzer SJ. CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 2006; 106: 483–93.
- 45 Nakajima T, Yamashita S, Maekita T, Niwa T, Nakazawa K, Ushijima T. The presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae. Int J Cancer 2009; 124: 905–10.
- 46 Basso D, Zambon CF, Letley DP, Stranges A, Marchet A, Rhead JL, Schiavon S, Guariso G, Ceroti M, Nitti D, Rugge M, Plebani M, et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology 2008; 135: 91–9.
- 47 Cover TL, Blanke SR. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol 2005; 3: 320–32.
- 48 Atherton JC, Cao P, Peek RMJr, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 1995; 270: 17771–7.
- 49 Rhead JL, Letley DP, Mohammadi M, Hussein N, Mohagheghi MA, Eshagh Hosseini M, Atherton JC. A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. Gastroenterology 2007; 133: 926–36.
- 50 Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003; 125: 1636–44.
- 51 Xia Y, Yamaoka Y, Zhu Q, Matha I, Gao X. A comprehensive sequence and disease correlation analyses for the C-terminal region of CagA protein of Helicobacter pylori. PLoS One 2009; 4: e7736.
- 52 Polk DB, Peek RMJr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010; 10: 403–14.
- 53 El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398–402.
- 54 Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003; 95: 1784–91.
- 55 Singh K, Ghoshal UC. Causal role of Helicobacter pylori infection in gastric cancer: an Asian enigma. World J Gastroenterol 2006; 12: 1346–51.
- 56 Fox JG, Beck P, Dangler CA, Whary MT, Wang TC, Shi HN, Nagler-Anderson C. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy. Nat Med 2000; 6: 536–42.
- 57 Whary MT, Sundina N, Bravo LE, Correa P, Quinones F, Caro F, Fox JG. Intestinal helminthiasis in Colombian children promotes a Th2 response to Helicobacter pylori: possible implications for gastric carcinogenesis. Cancer Epidemiol Biomarkers Prev 2005; 14: 1464–9.
- 58 Zen M, Ghirardello A, Iaccarino L, Tonon M, Campana C, Arienti S, Rampudda M, Canova M, Doria A. Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med Wkly 2010; 140( 13–14): 187–201.
- 59 Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007; 133: 659–72.
- 60 Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC. Gastric cancer originating from bone marrow-derived cells. Science 2004; 306: 1568–71.
- 61 Qian X, Huang C, Cho CH, Hui WM, Rashid A, Chan AO. E-cadherin promoter hypermethylation induced by interleukin-1beta treatment or H. pylori infection in human gastric cancer cell lines. Cancer Lett 2008; 263: 107–13.
- 62 Kitajima Y, Ohtaka K, Mitsuno M, Tanaka M, Sato S, Nakafusa Y, Miyazaki K. Helicobacter pyloriinfection is an independent risk factor for Runx3 methylation in gastric cancer. Oncol Rep 2008; 19: 197–202.
- 63 Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151: 121–8.
- 64 Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187–94.
- 65 Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772–81.
- 66 Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007; 133: 659–72.
- 67 Aebischer T, Meyer TF, Andersen LP. Inflammation, immunity, and vaccines for helicobacter. Helicobacer 2010; 15( Suppl 1): 21–28.
- 68 Taylor PR. Prevention of gastric cancer: a miss. J Natl Cancer Inst 2007; 99: 101–3.
- 69 Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735–40.
- 70 Rugge M, de Boni M, Pennelli G, de Bona M, Giacomelli L, Fassan M, Basso D, Plebani M, Graham DY. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010; 31: 1104–11.
- 71 Walker MM. Is intestinal metaplasia of the stomach reversible? Gut 2003; 52: 1–4.
- 72 Silva S, Filipe MI, Pinho A. Variants of intestinal metaplasia in the evolution of chronic atrophic gastritis and gastric ulcer. A follow up study. Gut 1990; 31: 1097–104.
- 73 Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, van Dekken H, Meijer J, van Grieken NC, Kuipers EJ. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010; 71: 1150–8.
- 74 Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006; 9: 245–53.
- 75 Kekki M, Samloff IM, Varis K, Ihamäki T. Serum pepsinogen I and serum gastrin in the screening of severe atrophic corpus gastritis. Scand J Gastroenterol Suppl 1991; 186: 109–16.
- 76 Broutet N, Plebani M, Sakarovitch C, Sipponen P, Mégraud F; Eurohepygast Study Group. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer 2003; 88: 1239–47.
- 77 Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol 2010; 105: 493–8.
- 78 de Vries AC, Kuipers EJ. Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies. Helicobacter 2007; 12 ( Suppl 2): 22–31.
- 79 González CA, Pardo ML, Liso JM, Alonso P, Bonet C, Garcia RM, Sala N, Capella G, Sanz-Anquela JM. Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. Int J Cancer 2010; 127: 2654–60.
- 80 González CA, Figueiredo C, Lic CB, Ferreira RM, Pardo ML, Ruiz Liso JM, Alonso P, Sala N, Capella G, Sanz-Anquela JM. Helicobacter pylori cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: a long term follow up in a high-risk area in Spain. Am J Gastroenterol 2011; 106: 867–74.
- 81 Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 2002; 50: 378–81.